معرفی
Professor Jeremy Hobart is a distinguished academic and clinician, serving as Professor of Clinical Neurology and Health Measurement at the Peninsula Schools of Medicine and Dentistry, Plymouth University. He is also a Consultant Neurologist at Plymouth Hospitals NHS Trust, where he integrates clinical expertise with research innovation in neurological disorders.
- Institution: Plymouth University
- School: Peninsula Schools of Medicine and Dentistry
- Clinical Affiliation: Plymouth Hospitals NHS Trust
His research is centered on improving measurement in neurology, particularly in multiple sclerosis (MS) and related conditions. Key areas include psychometrics, patient-reported outcomes, quality of life assessment, and the development and validation of rating scales. He employs advanced statistical methods such as Rasch analysis to ensure robust measurement tools in clinical trials and practice.
The recent trend in his publications highlights a strong focus on methodological rigor in MS research, including diagnostic delays, cardiovascular comorbidities in progressive MS, digital health tools for gait and balance, and critical evaluation of outcome measures in clinical trials. His work often involves large multicentre collaborations and contributes significantly to shaping best practices in neurology research.
While specific scientific awards are not listed in the provided text, his extensive publication record—including over 320 research outputs—and leadership in high-impact studies reflect broad recognition and influence in the field.
Professor Hobart plays a vital role in advancing both clinical neurology and research methodology. His work bridges patient care, measurement science, and digital innovation, contributing to more accurate diagnosis, better trial design, and improved patient outcomes in MS and autoimmune neurological disorders. He leads and contributes to major observational and interventional studies, often in collaboration with national and international research networks.
He is actively involved in research teams focused on MS and neuroimmunology, contributing to datasets and protocols that shape future research directions. His leadership in projects like the DIMES study and MS-STAT2 trial underscores his role in driving evidence-based improvements in neurological care.
